Simon Mitchell @mitchell.science · Dec 6 Diffuse Large B-cell Lymphoma (DLBCL) has lots of BCL2 and NF-kB. Both drive poor prognosis. Lots of people have tried inhibiting these. But NF-kB is 2 pathways, 5 proteins, and there are many BCL2-family proteins. We found previously (doi.org/10.3389/fonc...), each DLBCL has a unique "fingerprint".
1 likes 1 replies
?
Replies
Do these fingerprints predict drug responses? Yes! But what is going on with the U2932 cell line? Like lots of cancer it contains multiple cell populations with different genetics. This makes it great for figuring out how different cells in the same tumour might respond to a drug.